drugset / Trial / NCT02765555

First in Man Study of Safety, Tolerability and PK Profile of RBP-7000

NCT02765555

Phase 1 Completed 12 enrolled Indivior Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability and PK profile of a single dose of 60mg RBO-7000 in stable subjects with schizophrenia who are on medication other than risperidone.

Timeline

Start
2010-03
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 60 mg

Indications